Emetogenic Potential of Antineoplastic Agents
Emetogenic potential (high, moderate, low, or minimal risk) of oral and injectable antineoplastic agents.
Oncology
Cesarean Birth May Be Associated With Increased Childhood Cancer Risk
Significantly increased risk of any cancer and solid tumors; greatest risks seen for lymphoma and sarcoma
Manufacturing Deficiencies Delay Decision on Eflapegrastim
Eflapegrastim is a novel, long-acting G-CSF comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
Chemotherapy-Induced Nausea and Vomiting Guidelines: Prophylaxis
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
Oral AML Therapy Onureg Gets FDA Approval
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.
Acute Myeloid Leukemia: Type of Anthracycline May Not Affect Long-Term Outcomes
Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
FDA Approves Reblozyl for Anemia in Patients With Myelodysplastic Syndromes
The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
New Treatment Option Approved for Patients With Myelofibrosis
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
FDA Approves Novel Therapy for Relapsed, Refractory Multiple Myeloma
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Darzalex Gets Approval for Additional Multiple Myeloma Indication
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- Loading...
Loading...
Loading... 
Loading...